With a breakthrough in finding a solution for coronavirus the developers Pfizer and BioNTech describe it as a “great day for science and humanity.”
The vaccine has been tested on 43.500 people in six countries and no safety concerns have been raised so far.
Even though there still are huge challenges ahead, the announcement has been warmly welcomed by scientists describing themselves smiling “ear to ear” and some suggesting life could be back to normal by spring.
Speaking on this good news Pfizer chairman and chief executive Dr Albert Bourla said, “Today is a great day for science and humanity. The first set of results from our phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19.”
The companies plan to apply for emergency approval to use the vaccine by the end of the month. The UK has already ordered 30 million doses of the vaccine.
Per the data, two doses, three weeks apart, are needed. The Trials- in the US, Germany, Brazil, Argentina, South Africa and Turkey shows 90% protection is achieved seven days after the second dose.
If it is approved, the two companies say they will be able to supply 50 million doses by the end of this year and around 1.3 billion by the end of 2021. Each person will need two doses.